SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

MacroGenics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate Progress

Completed MGC028 Phase 1 dose escalation; selected lead indication for dose optimization across two

MGNX

Related stories